Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review
Pharmaceuticals · 14.04.2024 · 17 (4) · 501
DOI: 10.3390/ph17040501 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 14.04.2024. Verfasst von François Zammit und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
The increasing use of immune checkpoint inhibitors (ICI) in cancer therapy has brought attention to their associated neurotoxicities, termed neurological immune-related adverse events (n-irAEs). Despite their relatively rare incidence, n-irAEs pose a significant risk, potentially leading to severe, long-lasting disabilities or even fatal outcomes. This narrative review aims to provide a comprehensive overview of n-irAEs, focusing on their recognition and management. The review addresses a spectrum of n-irAEs, encompassing myositis, myasthenia gravis, various neuropathies, and central nervous system complications, such as encephalitis, meningitis, and demyelinating diseases. The key features of n-irAEs are emphasized in this review, including their early onset after initiation of ICIs, potential association with non-neurological irAEs and/or concurrent oncological response, the significance of ruling out other etiologies, and the expected improvement upon discontinuation of ICIs and/or immunosuppression. Furthermore, this review delves into considerations for ICI re-challenge and the intricate nature of n-irAEs within the context of pre-existing autoimmune and paraneoplastic syndromes. It underscores the importance of a multidisciplinary approach to diagnosis and treatment, highlighting the pivotal role of severity grading in guiding treatment decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institut Roi Albert II, Department of Medical Oncology, Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200 Brussels, Belgium.
Zitieren
APA
Zammit, F., & Seront, E. (2024). Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review. Pharmaceuticals, 17(4), 501. https://doi.org/10.3390/ph17040501
Vancouver
Zammit F, Seront E. Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review. Pharmaceuticals. 2024;17(4):501. doi:10.3390/ph17040501
BibTeX
@article{Zammit2024,
author = {Zammit, François and Seront, Emmanuel},
title = {Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {4},
pages = {501},
doi = {10.3390/ph17040501}
}
EUVIMED